Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterMune, Inc.

http://www.intermune.com

Latest From InterMune, Inc.

Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity

The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.

Clinical Trials Neurology

Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I

The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Review Pathway

Merck & Pfizer Win English Funding For Kidney Cancer Combo

NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.

United Kingdom Health Technology Assessment

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 
 
 
 

 

Coronavirus COVID-19 Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register